Literature DB >> 15573071

Targeted overexpression of leukemia inhibitory factor to preserve myocardium in a rat model of postinfarction heart failure.

Mark F Berry1, Timothy J Pirolli, Vasant Jayasankar, Kevin J Morine, Mireille A Moise, Omar Fisher, Timothy J Gardner, Paul H Patterson, Y Joseph Woo.   

Abstract

OBJECTIVE: Myocardial infarction leads to cardiomyocyte loss. The cytokine leukemia inhibitory factor regulates the differentiation and growth of embryonic and adult heart tissue. This study examined the effects of gene transfer of leukemia inhibitory factor in infarcted rat hearts.
METHODS: Lewis rats underwent ligation of the left anterior descending coronary artery and direct injection of adenovirus encoding leukemia inhibitory factor (n = 10) or null transgene as control (n = 10) into the myocardium bordering the ischemic area. A sham operation group (n = 10) underwent thoracotomy without ligation. After 6 weeks, the following parameters were evaluated: cardiac function with a pressure-volume conductance catheter, left ventricular geometry and architecture by histologic methods; myocardial fibrosis by Masson trichrome staining, apoptosis by terminal deoxynucleotidal transferase-mediated deoxyuridine triphosphate nick-end labeling assay, and cardiomyocyte size by immunofluorescence.
RESULTS: Rats with overexpression of leukemia inhibitory factor had more preserved myocardium and less fibrosis in both the infarct and its border zone. The border zone in leukemia inhibitory factor-treated animals contained fewer apoptotic nuclei (1.6% +/- 0.1% vs 3.3% +/- 0.2%, P < .05) than that in control animals and demonstrated cardiomyocytes with larger cross-sectional areas (910 +/- 60 microm 2 vs 480 +/- 30 microm 2 , P < .05). Leukemia inhibitory factor-treated animals had increased left ventricular wall thickness (2.1 +/- 0.1 mm vs 1.8 +/- 0.1 mm, P < .05) and less dilation of the left ventricular cavity (237 +/- 22 microL vs 301 +/- 16 microL, P < .05). They also had improved cardiac function, as measured by maximum change in pressure over time (3950 +/- 360 mm Hg/s vs 2750 +/- 230 mm Hg/s, P < .05) and the slopes of the maximum change in pressure over time-end-diastolic volume relationship (68 +/- 5 mm Hg/[s . microL] vs 46 +/- 6 mm Hg/[s . microL], P < .05) and the preload recruitable stroke work relationship (89 +/- 10 mm Hg vs 44 +/- 4 mm Hg, P < .05).
CONCLUSIONS: Myocardial gene transfer of leukemia inhibitory factor preserved cardiac tissue, geometry, and function after myocardial infarction in rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15573071     DOI: 10.1016/j.jtcvs.2004.06.046

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

Review 1.  Gene therapy for ischemic heart disease.

Authors:  Madhav Lavu; Susheel Gundewar; David J Lefer
Journal:  J Mol Cell Cardiol       Date:  2010-06-26       Impact factor: 5.000

2.  Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents.

Authors:  Hideaki Kanazawa; Masaki Ieda; Kensuke Kimura; Takahide Arai; Haruko Kawaguchi-Manabe; Tomohiro Matsuhashi; Jin Endo; Motoaki Sano; Takashi Kawakami; Tokuhiro Kimura; Toshiaki Monkawa; Matsuhiko Hayashi; Akio Iwanami; Hideyuki Okano; Yasunori Okada; Hatsue Ishibashi-Ueda; Satoshi Ogawa; Keiichi Fukuda
Journal:  J Clin Invest       Date:  2010-01-04       Impact factor: 14.808

Review 3.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

Review 4.  Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects.

Authors:  P Fischer; D Hilfiker-Kleiner
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

5.  Extracellular vesicular microRNAs as potential biomarker for early detection of doxorubicin-induced cardiotoxicity.

Authors:  Amelie Beaumier; Sally R Robinson; Nicholas Robinson; Katherine E Lopez; Dawn M Meola; Lisa G Barber; Barret J Bulmer; Jerome Calvalido; John E Rush; Ashish Yeri; Saumya Das; Vicky K Yang
Journal:  J Vet Intern Med       Date:  2020-04-07       Impact factor: 3.333

6.  Concomitant Activation of OSM and LIF Receptor by a Dual-Specific hlOSM Variant Confers Cardioprotection after Myocardial Infarction in Mice.

Authors:  Holger Lörchner; Juan M Adrian-Segarra; Christian Waechter; Roxanne Wagner; Maria Elisa Góes; Nathalie Brachmann; Krishnamoorthy Sreenivasan; Astrid Wietelmann; Stefan Günther; Nicolas Doll; Thomas Braun; Jochen Pöling
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

Review 7.  The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure.

Authors:  Thomas Kubin; Praveen Gajawada; Peter Bramlage; Stefan Hein; Benedikt Berge; Ayse Cetinkaya; Heiko Burger; Markus Schönburg; Wolfgang Schaper; Yeong-Hoon Choi; Manfred Richter
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

8.  Leukemia Inhibitory Factor Facilitates Self-Renewal and Differentiation and Attenuates Oxidative Stress of BMSCs by Activating PI3K/AKT Signaling.

Authors:  Youde Liang; Ruiping Zhou; Xin Liu; Lin You; Chang Chen; Xiaoling Ye; Wei Wei; Jie Liu; Jiawei Dai; Kaixiong Li; Xiangxiang Zhao
Journal:  Oxid Med Cell Longev       Date:  2022-09-05       Impact factor: 7.310

9.  Investigation into the effects of leukemia inhibitory factor on the bone repair capacity of BMSCs-loaded BCP scaffolds in the mouse calvarial bone defect model.

Authors:  Youde Liang; Ruiping Zhou; Xin Liu; Zhikang Liu; Lin You; Chang Chen; Xiaoling Ye
Journal:  J Bioenerg Biomembr       Date:  2021-06-10       Impact factor: 2.945

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.